Agex Therapeutics Inc   (AGE)
Other Ticker:  
Price: $0.3897 $0.02 5.182%
Day's High: $0.4171 Week Perf: 5.32 %
Day's Low: $ 0.38 30 Day Perf: -5.64 %
Volume (M): 55 52 Wk High: $ 1.00
Volume (M$): $ 22 52 Wk Avg: $0.59
Open: $0.38 52 Wk Low: $0.31

 Market Capitalization (Millions $) 15
 Shares Outstanding (Millions) 38
 Employees -
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -5
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Agex Therapeutics Inc
Agex Therapeutics Inc is a biotechnology company that specializes in the development of therapies for age-related diseases. The company is focused on the application of advanced machine learning and artificial intelligence technologies to identify and target the underlying biological mechanisms of aging. They aim to develop innovative treatments that can slow down the aging process and improve overall healthspan, thereby preventing or treating age-related diseases such as Alzheimer's disease, cardiovascular diseases, and cancer. Agex Therapeutics is also involved in the development of stem cell-based therapies and regenerative medicine approaches for age-related conditions.

   Company Address: 1101 Marina Village Parkway Alameda 94501 CA
   Company Phone Number: 671-8370   Stock Exchange / Ticker: NYSEAMER AGE
   AGE is expected to report next financial results on March 30, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Agex Therapeutics Inc

Aging Specialists Agex Therapeutics Inc Report a $-0.07 per Share Deficit in Q2 2023 Due to Declining Business

Declining Business Causes Increase in Deficit for Agex Therapeutics Inc
Agex Therapeutics Inc, a leading biotechnology company specializing in age-related diseases, recently reported its financial results for the fiscal period ending June 30, 2023. The company experienced a notable decline in business, which led to an increase in its deficit.
During the mentioned fiscal period, Agex Therapeutics Inc reported a deficit per share of $-0.07, representing no change from the previous year. This decline was accompanied by a decrease in revenue by -25% to $0.01 million, compared to the $0.01 million revenue recorded the previous year. Additionally, the revenue for the first quarter of 2023 deteriorated by -10% from $0.01 million to $0.00 per share.

Agex Therapeutics Inc

Agex Therapeutics Inc Achieves Balanced Books with $0.01 Million in Revenue for Q1 2023, Showing Promise for Profitability

Agex Therapeutics Inc, a biotechnology company that focuses on developing regenerative therapies, recently released its financial report for the fiscal first quarter of 2023. According to the report, Agex Therapeutics Inc managed to achieve balanced books of $0.00 per share in comparison to a loss of $0.06 per share from the previous year's first fiscal quarter. Moreover, the company's preceding reporting period showed earnings of $0.09 per share.
It is essential to understand that balanced books indicate that a company's revenue and expenses are equal, resulting in no profit or loss. Therefore, the fact that Agex Therapeutics Inc could break even implies that they have managed their finances appropriately, which is undoubtedly good news for the company and its investors.
However, despite achieving balanced books, the report showed that the company's revenue dropped drastically, plummeting 62.963% from $0.03 million to $0.01 million in the same reporting period of the previous year. Sequentially, the revenue improved, turning positive from $-0.11 million. A positive revenue sequence shows that the company has successfully moved from a loss-making venture to a profitable one.
Unfortunately, despite the revenue increase, Agex Therapeutics Inc's net loss for the fiscal first quarter of 2023 rose significantly to $-3.285 million, larger than $-2.159 million from the same quarter the previous year. This increase in loss could be attributed to several factors, such as increased expenses or the inability to increase revenue, amongst others.


Agex Therapeutics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com